TYME Tyme Technologies Inc.

1
-0.01  -1%
Previous Close 1.01
Open 1.03
Price To Book 11.11
Market Cap 111,950,937
Shares 111,950,937
Volume 50,538
Short Ratio
Av. Daily Volume 389,155

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 further data due 3Q 2019.
SM-88
Pancreatic cancer
Phase 2 final data to be reported late 2019 or early 2020.
SM-88
Prostate cancer
Phase 1/2 initiation announced May 23, 2019.
SM-88
Ewing’s sarcoma

Latest News

  1. TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019
  2. TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results
  3. The Tyme Technologies (NASDAQ:TYME) Share Price Is Down 83% So Some Shareholders Are Rather Upset
  4. Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019
  5. Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019
  6. TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas
  7. TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers
  8. Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th
  9. Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019
  10. Tyme Technologies to Participate at the SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on May 7th
  11. TYME Announces USAN Approval of Generic Name “Racemetyrosine” for SM-88
  12. TYME’s SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs
  13. TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer
  14. TYME Announces Dismissal of Class Action Lawsuit
  15. Tyme Technologies Announces Pricing of its $12 Million Registered Offering
  16. SHAREHOLDER ALERT: VALE TYME UXIN UMC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  17. DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  18. SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME  
  19. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TYME, GE and AVP
  20. 2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm